These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
595 related articles for article (PubMed ID: 10946880)
21. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients. Brokken LJ; Wiersinga WM; Prummel MF J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276 [TBL] [Abstract][Full Text] [Related]
22. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease. Tada H; Mizuta I; Takano T; Tatsumi KI; Izumi Y; Hidaka Y; Amino N Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621 [TBL] [Abstract][Full Text] [Related]
23. Increased levels of serum interleukin-18 in Graves' disease. Miyauchi S; Matsuura B; Onji M Thyroid; 2000 Sep; 10(9):815-9. PubMed ID: 11041460 [TBL] [Abstract][Full Text] [Related]
24. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases. Inukai T; Takanashi K; Takebayashi K; Fujiwara Y; Tayama K; Takemura Y Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968 [TBL] [Abstract][Full Text] [Related]
25. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease. Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159 [TBL] [Abstract][Full Text] [Related]
26. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease. Choo YK; Yoo WS; Kim DW; Chung HK Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556 [TBL] [Abstract][Full Text] [Related]
27. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter. Gedik O; Ozdemir T; Akalin S Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765 [TBL] [Abstract][Full Text] [Related]
28. Presence of antideoxyribonucleic acid antibody in patients with hyperthyroidism of Graves' disease. Katakura M; Yamada T; Aizawa T; Hiramatsu K; Yukimura Y; Ishihara M; Takasu N; Maruyama K; Kameko M; Kanai M J Clin Endocrinol Metab; 1987 Mar; 64(3):405-8. PubMed ID: 3493254 [TBL] [Abstract][Full Text] [Related]
29. Decrease of immunoglobulin G-Fc receptor-bearing T lymphocytes in Graves' disease. Mori H; Amino N; Iwatani Y; Asari S; Izumiguchi Y; Kumahara Y; Miyai K J Clin Endocrinol Metab; 1982 Sep; 55(3):399-402. PubMed ID: 6178751 [TBL] [Abstract][Full Text] [Related]
30. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease. Gamstedt A; Wadman B; Karlsson A J Clin Endocrinol Metab; 1986 Apr; 62(4):773-7. PubMed ID: 2869050 [TBL] [Abstract][Full Text] [Related]
32. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease. Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804 [TBL] [Abstract][Full Text] [Related]
33. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393 [TBL] [Abstract][Full Text] [Related]